The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients. We will conduct a nationwide, prospective clinical trial to examine the incremental value of using MRI for identification of liver metastases in pancreatic cancer patients.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board
No liver metastases on CT
At least 18 years old and able to provide informed consent
Expected pancreatic ductal adenocarcinoma based on CT scan
You may not be if
Metastatic disease
Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment
Comorbidity rendering major surgery unfeasible (inoperable)
No informed consent
Unable to undergo MRI (Kidney insufficiency (eGFR \< 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker)
Postoperative histology other than adenocarcinoma of pancreato-biliary origin.
MRI with liver-specific contrast performed during standard workup.
Clareo Health | Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery
